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9 Powerful strategy permits to rapidly characterise breakpoint
junctions: essential for a better understanding of the molecular
mechanism involving large rearrangements
C. Guittard1, C. The`ze1, M. des Georges1, M. Claustres1, M. Taulan1.
1Laboratoire de Ge´ne´tique Mole´culaire, CHU Montpellier, Montpellier, France
Although the vast majority of the 1600 CFTR gene alterations described are point
mutations or small deletions/insertions, large genomic rearrangements involving
one or several exons can contribute to unidentiﬁed alleles after complete scanning.
Thanks to the semi-quantitative ﬂuorescent PCR, we identiﬁed two novel gross rear-
rangements: a duplication of exon 2 and a deletion of exon 19. Using Light Cycler
technology, we successfully and rapidly delineated the rearrangement endpoints by
determining the relative copy number of a set of CFTR sequences ﬂanking exon 2
or exon 19. Fine mapping of the sequences bordering breakpoints was achevied
using direct sequencing.
We conﬁrmed a novel duplication spanning 5kb, c.54–4235_c.164+377dup4723.
This mutation in tandem and direct orientation is predicted to be in frame.
Moreover, we reported the ﬁrst complex CFTR rearrangement containing two
putative linked successive deletion events (c.3469–331_c.3469–294del37;c.3469–
189_c.3717+3822del4260pb). The presence of short direct repeats at the enpoints
of the both deletions suggested a possible replication slippage model.
The presence of regulatory elements that could inﬂuence the expression of the
CFTR gene and located in duplicated or deleted intronic regions will be discussed.
The identiﬁcation of breakpoint junctions of gross rearrangements in the CFTR
gene allows a better knowledge and understanding of their mutational mechanisms.
Moreover, the presence of potential regulatory elements identiﬁed in duplicated
or deleted regions could highlight genotype/phenotype differences in CF patients
harboring a deletion or insertion of the same exon with different breakpoints.
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10 MALDI-TOF mass spectrometry-based assay for CFTR gene
mutation analysis in cystic ﬁbrosis newborn screening programs
P. Ran˜a-Dı´ez1, C. Colo´n2, J.R. Alonso-Ferna´ndez2, J.M. Fraga2, A. Carracedo1,
F. Barros1. 1Fundacio´n Pu´blica Galega de Medicina Xeno´mica, Santiago de
Compostela, Spain; 2Unidade de Metabolopatı´as, Departamento de Pediatrı´a,
Complexo Hospitalario Universitario de Santiago, Universidade de Santiago,
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The delay in the diagnosis of Cystic Fibrosis is very common and the early diagnosis
of the disease through newborn screening programs enables to do therapeutic
interventions and genetic counseling before the presentation of the symptoms.
Nowadays most part of screening programs have introduced DNA tests in their
screening algorithms to avoid the problems related to using IRT as exclusive
biomarker.
Diverse commercial kits have been developed for the CFTR mutation testing
worldwide. Most of them generally include the testing of a few number of
mutations following the American College of Medical Genetics/American College
of Obstetricians and Gynecologists recommendations. The main problem using
these kits in newborn screening programs is that they generate an important number
of false negatives in populations with a high diversity of CFTR mutations like
European Mediterranean countries.
In order to avoid this important bias we developed an in-house assay using the
Sequenom MassARRAY® iPLEX system which allows to study simultaneously a
broad panel of more than 180 variants (including mutations and polymorphisms).
The iPLEX® assays are based on a multiplex PCR followed by a single base primer
extension reaction. The primer extension products are analyzed using MALDI TOF
MS. To validate this technology we have tested it in a newborn screening program
for cystic ﬁbrosis since 2006. The sensitivity of this technology makes it possible
to use a fragment of the same blood spot used for the IRT measure.
11 Sequence and MLPA analyses found CFTR mutations in all
patients with classic CF
I. de Monestrol1, V. Adermark1, H. Cuppens2, L. Hjelte1. 1Stockholm CF
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Background:Mutation speciﬁc treatments for CF will soon be available. To become
eligible for such treatments the CFTR mutations have to be identiﬁed.
Aim: To ﬁnd CFTR mutations in all CF patients at Stockholm CF Centre.
Results: For 212 patients diagnosed with pathological sweat chlorides >60mmol/L
and CF symptoms, genetic analyses were primarily performed with Oligonucleotide
Ligand Assay (OLA) by Abbott Molecular detecting 33 CFTR mutations. For
those with one or two unknown alleles analyses with sequencing and Multiplex
Ligation-mediated Probe Ampliﬁcation (MLPA) of the CFTR gene were also
done. We found rare mutations and deletions such as, Y109N, 711+3A−G, 1506L,
3130delA, Y569D, 621+1T, 3789insA, D110H, 1548delG, Q493X, T1086I, L206W,
L732X, S549I, 1525−2A<G, deletion 2, deletion13−14a and deletion 21. For all
patients with classic CF we found two CFTR mutations. For 10 patients with an
atypical/non-classic CF, for example late diagnosis of mild CF symptoms, no genetic
support for the CF diagnosis was given. Altogether CFTR mutations were found in
96% (408/424) of CF alleles. However for only 88% (372/424) the mutations could
be classiﬁed according to the ﬁve CFTR functional classes, which will be needed
in the future when mutation speciﬁc treatments will become available.
Conclusion: For patients with classic CF and unknown mutations further analyses
of the CFTR gene should be performed to ﬁnd CFTR mutations. There is also a
need for more functional studies regarding CFTR mutations.
12 Identiﬁcation of large deletions and duplications in the CFTR gene
using Multiple Ligation-dependent Probe Assay (MLPA), including
one novel duplication and two novel deletions
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The vast majority of CFTR mutations are simple nonsense, missense, frameshift or
splicing defects, but in any population there remains a small group of CF patients
whose mutations are unidentiﬁed, even after sequencing the entire gene. Several
groups have reported larger deletions and duplications, involving one or more
complete exons, within the CFTR gene. We have analysed 86 CF patients who
have been sequenced for all 27 exons and their intron/exon boundaries and whose
CF-causing mutations remain unidentiﬁed. 4 patients were found to have different
deletions, 2 of which were previously undescribed; we also found 2 patients with
duplications, one of which was novel.
Although ascertainment of CF plays a signiﬁcant role in the calculation of mutation
frequencies, we estimate that large deletions and duplications account for a small
but signiﬁcant proportion of all CF-causing mutations in our population.
